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Abstract 
Introduction: Beyond documentation of high prevalence rates, research has not examined the 
qualities and characteristics of musculoskeletal symptoms in cancer survivors, possibly because 
measures have not been validated specifically for the assessment of these symptoms in 
survivors. We report here on a new measure of muscle and joint symptoms for survivors of 
hematologic malignancies and hematopoietic cell transplantation (HCT). 
Methods: In a cross-sectional design, 130 adults, 5-20 years after HCT, completed patient-
reported outcomes. Assessment included musculoskeletal symptoms on the Muscle and Joint 
Measure (MJM), as well as health-related quality of life and treatments. 
Results: Principal components analysis using promax rotation revealed four subscales for the 
MJM with item factor loadings above 0.50: muscle aches or stiffness (myalgias), joint pain, 
stiffness or swelling (arthralgias), muscle cramps and muscle weakness. Variance explained by 
the total score was 77%. Internal consistency reliabilities of the subscales and total score 
ranged from 0.86 to 0.93. Validity was confirmed by correlations with the Short Form-36 bodily 
pain, physical function and vitality subscales, the Fatigue Symptom Inventory, and the Symptom 
Checklist-90-R depression (all P<.001).  
Conclusions: Musculoskeletal symptoms in survivors who received HCT can be measured 
reliably and validly with the MJM. The measure requires testing to establish its psychometric 
properties with other diagnostic and treatment groups.  
Implications for Cancer Survivors: The MJM has potential research and clinical value for 
addressing the musculoskeletal symptoms of survivors. The measure may assist with examining 
the mechanisms as well as treatments for these symptoms, which are among the most 
prevalent in long-term cancer survivors. 
 
Key Words: Cancer survivors, musculoskeletal, symptoms, myalgias, arthralgias, muscles, 
joints, measurement
Measuring Musculoskeletal Symptoms in Cancer Survivors 3 
Introduction 
Musculoskeletal symptoms are some of the most widely documented and persistent 
complications seen after a variety of cancer treatments[1]. High rates of musculoskeletal 
complaints and limitations in physical capacity are reported by breast cancer survivors[2,3] and 
adult survivors of childhood cancers[4,5]. Similarly, following high dose treatment and 
hematopoietic cell transplantation (HCT), these symptoms have been reported across most 
studies of long-term survivors[6-9]. However, understanding and treatment of these symptoms 
have been limited by lack of measures that characterize and evaluate their severity and impact. 
Physical recovery occurs for most HCT survivors by one year after treatment and then 
remains fairly stable through five years[10]. Despite good physical function in at least 75% of 
long-term survivors, recent late follow-up case-control studies have documented an increased 
number of health problems and poorer physical function in these long-term survivors relative to 
controls[7,11,12]. Our own research has found that, among 10-year survivors of adult HCT, 
some of the most prevalent symptoms are musculoskeletal, with 35% having one or more 
symptoms versus 17% of matched controls, even after eliminating from calculations those 
survivors with avascular necrosis related to corticosteroid treatment for chronic graft versus host 
disease (GVHD)[7]. Survivors of childhood HCT report more muscle weakness (5.5% vs 1.6% 
for controls) and pain (21% vs 10% for controls), although specific locations or types of pain 
were not categorized[4]. Alkylating agents and total body irradiation (TBI), used regularly in 
HCT, have been associated with increased prevalence of musculoskeletal complications[7].  
Limited literature has supported hypotheses about etiology or mechanisms for 
musculoskeletal symptoms in HCT survivors. Some research indicates that musculoskeletal 
problems existed prior to transplant and continued in the post-transplant period[13]. Treatment-
related factors may also play a role. Patients who received allogeneic HCTs (transplant of stem 
cells from a donor) and had chronic GVHD were more likely to report muscle weakness than 
patients without chronic GVHD[4], indicating that long-term immunosuppression may be a key 
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factor. In a separate study, patients with hematologic malignancy who received TBI with or 
without HCT were more likely to have decreased muscle strength than patients who did not 
receive TBI[14].  
Inconsistencies and inadequacies in measurement of musculoskeletal symptoms restrict 
our ability to characterize these symptoms across diseases or treatments, model risk factors, 
understand the potentially varying mechanisms that cause these long-term deficits and, 
ultimately, determine options for preventing or treating these long-term complications. Despite 
the prevalence of reports of musculoskeletal problems, we are aware of no measures that 
permit description of the characteristics, intensity, or duration of these symptoms in oncology 
beyond general symptom measures[15,16]. The most commonly used and standardized cancer-
specific measures of function and symptoms are designed for use during the acute treatment 
period. Generic, non-disease-specific measures of health-related quality of life with population-
based norms, such as the widely used Short Form Health Survey-36 (SF-36)[17], are not 
designed to assess specific symptoms or functional deficits reported by cancer survivors[18]. 
Further, the similarities or distinctions between fatigue, which is relatively better described in 
cancer survivors, and musculoskeletal symptoms have not been delineated. Our own 
experience suggests that fatigue in long-term survivors is more associated with muscle 
weakness and loss of muscle mass (sarcopenia), and the related lack of stamina and strength, 
than with the tiredness that characterizes fatigue during treatment. Consequently, we have 
included weakness in our consideration of the characteristics and measurement of muscle and 
joint symptoms. 
To address the deficit in knowledge about musculoskeletal complications in long-term 
HCT survivors, we determined that a measure was needed that would permit reliable and valid 
characterizing of musculoskeletal symptoms. Therefore the goal of the investigation presented 
here was to establish the psychometric properties of a new measure of muscle and joint 
symptoms for use with HCT patients, and potentially with other cancer survivors, including 
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definition of subscales based on factor analysis, internal consistency reliability, and validity of 
the measure relative to established scales and diagnoses or treatments that would be expected 
to be associated with increased muscle or joint symptoms. For convergent validity, we 
hypothesized large size correlations (r>0.50) of Muscle and Joint Measure (MJM) scores with 
physical function and bodily pain as well as with depression, since depression is consistently 
associated with musculoskeletal and other chronic pain[19]. We predicted that patient reported 
vitality and fatigue also would have large size correlations with weakness on the MJM scores. 
For divergent validity, we thought it important to demonstrate that MJM symptoms are largely 
independent of general mental health and anxiety, thus we predicted small to medium 




All regionally residing hematologic malignancy survivors who underwent a first HCT 5 to 
20 years before evaluation at a major transplant center in Seattle were identified using the 
center’s research database. Since aims of the broader research included onsite tests, those 
who lived in the region defined by a 98XXX zip code (within about 3 hours driving distance) 
were contacted with a letter of approach if they were between the ages of 18 and 49 years old. 
The age limit of 49 at time of first contact was set to reduce confounding of results for the 
broader study aim of characterizing musculoskeletal complications associated with HCT by 
excluding those who have musculoskeletal problems potentially attributable to natural aging. 
Exclusion criteria for participation in the patient-reported outcomes (PRO) included having a 
recurrence or second cancer that was actively treated in the previous two years (other than 
basal or squamous cell skin cancer), and inability to read and understand English adequate to 
complete the assessments. This paper reports only on the PRO component of the study. 
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Procedure 
The study design was cross-sectional. All procedures were approved by the Fred 
Hutchinson Cancer Research Center Institutional Review Board. Potentially eligible participants 
were sent up to three introductory letters for the study. Study staff called all survivors who did 
not actively opt-out to explain the study details, screen for eligibility and obtain oral consent. 
Survivors completed assessments online unless they requested paper and pen versions. Those 
requesting paper and pen forms were mailed the forms and information for survey completion, 
including a stamped return envelope for returning the materials. Participants who did not 
complete the assessment within two months, and after follow-up phone calls, were contacted for 
an abbreviated assessment by phone. Study staff were available in person when assessments 
were done on site or by phone to answer questions or address any concerns. Transplant-related 
medical information was abstracted from the center’s research medical records. 
Measures 
 Muscle and Joint Measure (MJM). The MJM was developed through a process of 
qualitative interviews followed by scale development. After IRB approval of the procedure, an 
initial group of 31 nationally dispersed 5 to 10 year HCT survivors who had been consented and 
enrolled in other longitudinal studies[7,20] agreed to participate in a qualitative, semi-structured 
phone interview. The interview was designed to determine the features of musculoskeletal 
symptoms, including characteristics, severity, temporal qualities, and impact on activities, in 
preparation for development of a PRO measure.  
The MJM was prepared using qualitative responses from these interviews. The measure 
had four sections: muscle cramps (cramps), muscle weakness (weakness), muscle aches, 
pains, and stiffness (myalgias), and joint pain, swelling or stiffness (arthralgias). Each section 
repeated content about temporal qualities, severity, and impact. A temporal item asked about 
“How much of the time do you have <problem> in a usual month?” with responses from 1 = “it is 
completely unpredictable” to 9 = “all the time.” A severity item asked respondents to “rate how 
Measuring Musculoskeletal Symptoms in Cancer Survivors 7 
severe your <problems> are on the 0 to 10 scale below by circling the number that best fits how 
severe your problems are usually or most of the time,” with responses from 0 = “no problem at 
all” to 10 = “problem as bad as can possibly be.” Impact items asked respondents to rate 
whether problems wake the person when sleeping, or limit emotional well-being, physical 
activities, sitting or standing, walking, social activities or work, with response options from 1 = 
“not limited at all” to 4 = “yes, stop me from doing this activity.” Items asked only within specific 
sections included: 1. “When do you have muscle cramps or spasms (responses: 1 = “only when 
exercising” to 4 = “day and night”)? 2. “Does muscle weakness make you need to take naps or 
sleep longer” (responses: 1 = “rarely or not at all” to 4 = “3 to 5 times a week, or more”)? 3. 
“How much difficulty do you have, or how limited are you, when moving your joints” (responses: 
1 = “not at all” to 4 = “severely”). The measure had a total of 38 items, plus descriptive questions 
about location of cramps, myalgias and arthralgias, whether the symptoms predated HCT or 
when they began, as well as diagnoses and types of treatment for these problems. These latter 
items were not included in the psychometric analyses for the MJM. Higher scores on the MJM 
indicated increased symptom severity. 
Other outcomes. Medical records review provided cancer diagnosis, transplant regimen, 
date of transplant, occurrence of systemic chronic GHVD, and dates of relapse or second 
malignancy. Relapse and second malignancies were confirmed by PRO. Standard self-report 
items captured information on age, gender, race and ethnicity, education, income, marital 
status, treatment history and diagnosed medical problems. To distinguish major symptoms from 
infrequent aches and pains, survivors reported current medications taken at least weekly for 
chronic GVHD, or for any musculoskeletal pain problem. 
Additional PRO measures reported here included the Short Form 36 Health Survey, 
version 2 (SF-36), the Fatigue Symptom Inventory (FSI), and the depression and anxiety 
subscales of the Symptom Checklist-90-R (SCL-90-R).  
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SF-36 (version 2). The SF-36 has been widely used to assess health-related quality of 
life in studies of cancer survivors, and has age and gender-specific norms for the United 
States[17]. We utilized the standardized T scores for calculating the 8 subscale domains. This 
report focuses on the bodily pain, physical function, vitality and mental health subscales. The 
instrument’s internal consistency, validity among different medical groups, and test-retest 
reliability have been documented to be excellent[17,21,22]. Higher scores on the SF-36 indicate 
better function. 
FSI. The FSI has been frequently used as a measure of fatigue in cancer survivors[23]. 
It has a total score based on 13 items that assess the duration, intensity and disruptiveness of 
fatigue and its impact on quality of life. It was designed for use in the cancer population and 
evidence supports its reliability and validity[23,24]. Higher scores on the FSI indicate greater 
fatigue. 
SCL-90-R Depression and Anxiety. The SCL-90-R depression and anxiety scores were 
used to evaluate secondary aims of mood associations with musculoskeletal symptoms. The 
SCL-90-R measure is well standardized and widely used in medical studies, with strong 
reliability and validity with clinical populations, including cancer patients[25]. Higher scores on 
the SCL-90-R indicate increased depression or anxiety. 
Statistical Analyses 
 Descriptive and inferential analyses were performed using Statistical Package for the 
Social Sciences version 17.0 (SPSS; SPSS Inc, Chicago, IL). We calculated descriptive 
statistics for the demographic and treatment characteristics of the participants. The sample size 
met criteria defined by Sapnas and Zeller[26] as sufficient to perform factor analysis. Since 
factors were predicted to be correlated, principal components analysis using promax rotation 
was performed to examine the factor structure of the MJM. To achieve the most parsimonious 
measure, items were deleted if they did not load on a single factor with loadings >0.50 and if 
they did not contribute to explained variance or internal consistency reliability. Internal 
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consistency reliability of the items in the resulting subscales and the total score were calculated 
using Cronbach’s alpha. Pearson correlations, one-way analyses of variance, or t tests were 
used to examine differences in MJM subscales and total score across medical and demographic 
factors. For convergent and divergent validity testing, we used Cohen’s criterion[27] to interpret 
the magnitude of correlation coefficients (r < 0.3 = small, 0.3 ≤ r <0.5 = medium, r ≥ 0.5 = large). 
For convergent validity, using Pearson correlations we tested our predicted large associations 
for the MJM subscales and total score with the SF-36 physical function, bodily pain, and vitality 
subscales, FSI total score and SCL-90-R depression. For divergent validity testing, using 
Pearson correlations we tested our predicted small to moderate associations for the MJM 
subscales and total score with the SF-36 mental health and SCL-90-R anxiety subscales. 
Additional t tests were conducted to validate the MJM relationship to medication use that we 
expected would be related to musculoskeletal symptoms including chronic GVHD medications 




Of the 190 potentially eligible participants identified in the institutional medical record 
database, 172 could be contacted for screening. Of these, 144 participants were eligible and 
agreed to participate (Figure 1). Of the 144 participants, 130 (90%) completed the PRO that 
included the MJM items. Of these 130 participants, 28 (22%) completed an abbreviated phone 
assessment that did not include the FSI or the SCL-90-R, so are not included in analyses 
reporting those measures.  
Table 1 presents demographic and medical characteristics of the N=130 study 
participants. Approximately half of the sample was male (52%). Mean age at the time of 
transplant was 28.2 years (SD 9.9) and mean age at the time of assessment was 39.5 years 
(SD 8.8). Time between HCT and the date of assessment ranged from 5.0 to 20.9 years, and 
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the mean time since transplant was 11.3 years (SD 4.6). No participants had current evidence 
of active disease (as required for eligibility), or had received a second transplant, though 7 (5%) 
had evidence of relapse after their transplant, treated with immune-modulators, but not within 
the 2 years before assessment. Nine survivors (7%) indicated they had been diagnosed with a 
second cancer since their transplant, 5 of these were localized skin cancers, and none occurred 
in the 2 years before assessment as required for study eligibility. The majority self-identified as 
Caucasian (N=117, 90%) and non-Hispanic, non-Latino (N=123, 95%), without a college degree 
(68%), and married (61%). In addition, a majority reported working full time for pay (63%) and 
had a total household income of $40,000 or greater (67%).  
Analyses revealed no significant differences between phone interview responders and 
complete assessment responders on the demographic or medical characteristics in Table 1, or 
for any of the outcomes tested including MJM subscale or total scores (all P>.10). 
Muscle and Joint Measure Psychometrics 
Before conducting psychometric analyses of the MJM, item response patterns and 
content of the item responses and written comments were reviewed. No unusual patterns were 
identified in responses. Descriptive statistics for items tested in the original principal 
components analysis are listed in Table 2.  
The final principal components analysis of the MJM items revealed the presence of five 
main components with eigenvalues exceeding 1 (Table 3). Based on Catell’s[28] scree test, we 
retained these five factors. Items that did not load on one of the five factors or did not contribute 
additional explained variance or reliability were deleted from the measure. In total, 25 items 
remained in the final factor structure, with one factor each comprising weakness, myalgias and 
arthralgias. The cramps subscale included two factors; intensity and impact loaded separately. 
The five factor solution with 25 items explained a total of 76.8% of the variance (Table 4). 
Overall internal consistency reliability for the 25 items was α = 0.93. The communalities for each 
of the items were above 0.5, ranging from 0.58 to 0.87. 
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Each factor was then examined in principal components analysis with promax rotation to 
determine the psychometric support for each subscale to be used as a stand alone scale (Table 
4). Items for arthralgias, myalgias, and weakness subscales each loaded on a single factor, 
while cramps again loaded on 2 factors. Each subscale independently explained more than 70% 
of the variance when examined alone, each had factor loadings for the items above 0.60, and 
each had internal consistency reliability of α > 0.85 (Table 4).  
The four content-based subscales consisted of six or seven items each, with intensity 
including two items or four items for cramps, and impact including four items for each subscale, 
except three items for cramps. To equally weight the intensity and impact contributions to 
subscales and the total score, means of the intensity and impact items were calculated 
separately. We then computed an overall mean for each subscale from these two component 
means. For the total MJM score, we computed an overall mean using each of the four subscale 
means. Intercorrelations between the MJM total score and subscales, as well as between 
subscales were medium to large in size, with all r > 0.30 (Table 5). 
Items measuring spine and neck pain and stiffness were included in the original 
assessment items, with parallel structure to joints/arthralgias. However, these items did not add 
further unique information to the factor structure, explained variance, or reliability of the MJM.  
Each subscale included descriptive items such as where in the body the symptoms were 
located. For example, joints included options for knees, hips, hands or finger, shoulders, other 
places. Spine and neck included specifying location options for neck, upper spine, middle spine 
and/or lower spine. In examination of the responses and descriptive information, 69% of 
respondents reported no spine or neck symptoms (subscale score = 0) and over half of those 
reporting problems indicated that spine and neck symptoms pre-dated their HCT. 
Muscle and Joint Measure Validity Testing 
Table 6 displays convergent validity testing, which confirms hypothesized correlations 
between MJM scores and the SF-36 physical function, bodily pain and SCL-90-R depression (all 
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r > 0.40 and all P < .001). SF-36 vitality and FSI subscales also correlated with MJM scores, but 
vitality was not selectively more strongly correlated with the MJM weakness subscale as we had 
predicted. Fatigue and weakness shared 40% of their variance (r = .63, P < .001), about the 
same as fatigue and muscle aches (r = .62). In general, correlations with cramps were weakest 
in validity testing. As predicted, physical function, bodily pain and depression were more 
strongly correlated with MJM scores than were mental health and anxiety. Ongoing use of 
systemic chronic GVHD medications was related most strongly to greater MJM weakness (t = -
3.3, P < .001), and also to MJM arthralgias (t = -2.4, P = .02) and total score (t = -2.3, P = .02), 
but not to cramps (t = -0.13, P = .90) and only trended toward an association with myalgias (t = -
1.8, P = .08). On the other hand, a history of GVHD was unrelated to all MJM scores (all P > 
.35). Use of pain medication at least weekly was associated with higher MJM pain-related 
subscale scores (cramps: t = -2.1, P = .04, arthralgias: t = -4.2, P < .001, myalgias: t = -3.2, P = 
.002). However, weakness scores did not differ between those who did or did not use pain 
medications at least weekly (P =.30), nor, for these long-term survivors, were any MJM scores 
related to receipt of TBI during conditioning for HCT (all P >.20). For divergent validity testing, 
as predicted, MJM scores generally had small to moderate size correlations with SF-36 mental 
health and SCL-90-R anxiety (Table 6). Although still significant these correlations were lower 
than for physical function, bodily pain and depression. 
Of note, for these survivors all aged 18-50, age was not consistently related to MJM 
scores: total score r = 0.19 (P = .03), cramps r = 0.24 (P = .01), arthralgias r = 0.14, myalgias r = 
0.08 (ns), weakness r = 0.09, (ns). 
 
Discussion 
This study provides evidence that the Muscle and Joint Measure (MJM) can be a useful 
new tool to assess musculoskeletal symptoms in HCT survivors, and potentially in other cancer 
survivors. All of the factor loadings were above 0.50 for the overall scale and within the 
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individual subscales, with explained variances above 70% for each. Internal reliabilities for the 
four subscales and total score were above 0.85.  
Validity testing confirmed that the strongest associations occurred between bodily pain 
and arthralgias and myalgias, and between fatigue and both weakness and myalgias. Similarly, 
use of pain medication was related to higher subscale scores for arthralgias, myalgias and 
cramps, but not greater weakness. As predicted, the subscales of the MJM were least 
associated with general mental health and anxiety, while associations with depression were 
stronger, especially for myalgias and weakness. These results suggest that the MJM is 
capturing physical symptoms without major interference from emotional factors. Further, these 
results confirmed previously noted associations between weakness and current use of chronic 
GVHD medications[4], but did not replicate previous findings of higher musculoskeletal 
complaints for those who had a past history of chronic GVHD or who received TBI in their 
conditioning before HCT[14]. This latter lack of association with treatment type may result from 
the many years (5-20) since treatment and the mediating events since then. It is also possible 
that with physiologic tests measuring strength and flexibility, deficits would be found that are not 
captured in patient-reported symptom measures. 
Still lagging in the field of survivorship research are longitudinal studies that explore the 
trajectory of musculoskeletal symptoms after cancer treatment. In part, this gap is explained by 
the diversity and complexity of these symptoms, and the lack of identified symptom clusters that 
would move forward the understanding of both measurement and mechanisms as has occurred 
with the science and treatment of symptoms during active anti-cancer therapy. The current 
results on the measurement of muscle and joint symptoms long after treatment, including their 
associations with pain, depression and fatigue, may offer opportunities to examine underlying, 
linking mechanisms in long-term HCT survivors as have been identified for these symptoms 
during acute treatment or in non-HCT cancer survivors including inflammatory cytokines, 
muscle-related growth factors and hormonal changes [29-34]. Accurate measurement of muscle 
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and joint symptoms in survivors, beginning with a clear understanding of prevalence and 
characteristics of these symptoms, similarly may help advance the understanding of 
mechanisms for these long-term complications.  
Of note, we found that spine and neck aches, pain and stiffness did not explain further 
variance or improve the reliability of the MJM measure, nor did they occur independently of 
other MJM symptoms. Furthermore, on closer examination of the location and other descriptive 
item responses about these symptoms, we found that spine and neck symptoms were reported 
by 31% of survivors, with over half of the onset events predating transplants. Thus it seems that 
spine and neck symptoms are not a prevalent consequence of HCT. Nonetheless, these 
symptoms are reminders that survivors experience both post-treatment and premorbid pain 
syndromes that need to be addressed when evaluating and providing integrated treatment 
recommendations for survivors.  
Development of adequate assessments for musculoskeletal symptoms in HCT survivors 
as well as other cancer survivors is important also because many of these symptoms may be 
treatable. Anti-inflammatory or other pain medications or even antidepressants may be helpful in 
treating some arthralgias or myalgias[35]. Behavioral interventions which include exercise and 
strength training can also alleviate pain, stiffness and weakness[36-40]. However, further 
intervention studies focused specifically on methods to decrease musculoskeletal syndromes in 
HCT and other cancer survivors are needed.  
The current study focused on HCT survivors. The items of the MJM are not cancer-
specific so the measure could be used with general population control groups or patients with 
other chronic illnesses, but requires confirmatory psychometric testing with non-HCT cohorts. 
Next steps are underway to test the MJM with other cancer populations and with general 
populations to allow comparison of symptoms with normative rates, severity and characteristics. 
Also of value would be to examine MJM findings in cancer survivors relative to other chronic 
disease populations with prevalent musculoskeletal symptoms.  
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This investigation offers several strengths and limitations. First, this is the first report that 
we know of that provides a measure developed specifically to collect information on 
musculoskeletal symptoms in a cancer survivor population. In addition, we utilized a 
comprehensive sample of HCT survivors from our center, with a wide range of survivorship 
years and balanced representation of genders, and were able to achieve a high response rate.  
A limitation in the current validation the MJM is that the measure was not compared with 
established and validated rheumatology scales to determine if this scale is correlated with them 
or to compare sensitivity and specificity of them in the HCT population. The Western Ontario 
and MacMaster Universities Osteoarthritis Index (WOMAC) is the most widely used and similar 
measure, not specific to an anatomical location, that we found in publication searches[41]. 
Although we administered this measure, the scale developers do not permit the WOMAC to be 
used in validation research for other measures, therefore we are not able to include those 
results here. Future research should look at the MJM relative to arthralgia and myalgia scales 
developed and tested in non-cancer populations. Examples include the Health Assessment 
Questionnaire (HAQ and modified MHAQ and MDHAQ) and the Arthritis Impact Measurement 
Scales (AIMS) designed for rheumatic diseases[42-44]. Other measures specific to the upper 
extremity are also available and tested primarily with rheumatology patients, such as the 
Disabilities of the Arm, Shoulder and Hand Outcomes (DASH) Questionnaire and the Score for 
the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (SACRAH or 
M-SACRAH)[45,46]. These would also be of value to test relative to the MJM for sensitivity and 
specificity in detecting disabilities related to cancer and HCT survivorship. Of interest, in testing 
many of these scales, investigators have used the SF-36 to validate the measures, as was done 
with the current research, or to compare their relative sensitivity and specificity[45,47,48].  
Other limitations include the relatively small sample size and the limited generalizability 
based on use of survivors from one transplant center, with a history of hematologic 
malignancies, who received HCT as part of their treatment and lived in the Western Washington 
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region. Further testing is needed to assure that results and psychometrics apply equally to 
survivors from a broader geographic region, from other transplant centers, or who received 
other types of treatment for other malignancy diagnoses. Another limitation is the dependence 
on PRO for establishing validity. Physiologic and functional measures would extend the validity 
testing to include the association of PRO to these outcomes. Future research needs to validate 
the MJM against quantitative measures of function in multiple anatomic areas. Further, our 
dependence on remote contacts through mail, phone or internet responses may increase the 
potential for unknown enrollment biases. 
In summary, the psychometrics for the MJM suggest that this measure may be a 
promising tool for further research into the understanding musculoskeletal symptoms commonly 
reported by long-term survivors of cancer. As more patients survive cancer, and specifically 
HCT, increasing attention must be paid to not only curing the underlying disease, but also to 
recognizing and improving long-term physical, psychological, and social sequelae of treatment. 
Multi-dimensional assessment that includes, but is not restricted to, musculoskeletal symptoms 
will support progress in health outcomes research on survivors.  
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Table 1. Demographic and medical characteristics 
 N = 130 








Years since Transplant, Mean, Median (SD) 
 5.0 - 9.9, N (%) 
10.0 - 14.9, N (%) 
15.0 – 20.9, N (%) 










Race, N (%) 
Caucasian 












Ethnicity, N (%) 
Hispanic, Latino 
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Table 1. Demographic and medical characteristics cont’d 
Education, N (%) 
High School or Less  
Vocational School or Some College  





Income, N (%) 
< $40,000 








Marital Status, N (%) 





Diagnosis, N (%) 
Acute Leukemia 
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Table 1. Demographic and medical characteristics cont’d 


















Chronic Graft versus Host Disease History: Yes, N (%) 54 (42) 
HCT = hematopoietic cell transplantation 
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Arthralgias How much of the time (daily 
vs. weekly vs. monthly)? 
2.03 2.53 0-9 0-9 Yes 
Arthralgias How much difficulty moving 
your joints? 
.50 .79 0-3 0-3 No* 
Arthralgias Severity usually or most of 
the time? 
2.14 2.93 0-10 0-10 Yes 
Arthralgias Wake you when are 
sleeping? 
.46 .94 0-3 0-3 Yes 
Arthralgias Impact your emotional well-
being? 
.31 .67 0-3 0-3 Yes 
Arthralgias Limit or prevent physical 
activities?  
.57 .86 0-3 0-3 Yes 
Arthralgias Limit or prevent sitting or 
standing? 
.30 .59 0-2 0-3 Yes 
Arthralgias Limit or prevent walking? .26 .57 0-2 0-3 No* 
Arthralgias Limit or prevent work 
activity? 
.31 .65 0-3 0-3 No 
Arthralgias Limit or prevent social 
activity? 
.16 .48 0-3 0-3 No* 
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Myalgias How much of the time 
(daily vs. weekly vs. 
monthly)? 
2.32 2.74 0-9 0-9 Yes 
Myalgias Severity, usually or most of 
the time? 
2.81 3.41 0-10 0-9 Yes 
Myalgias Wake you or when you are 
sleeping? 
.52 .97 0-3 0-3 Yes 
Myalgias Impact your emotional 
well-being? 
.38 .66 0-3 0-3 Yes 
Myalgias Limit or prevent physical 
activities?  
.47 .74 0-3 0-3 Yes 
Myalgias Limit or prevent sitting or 
standing?  
.31 .60 0-3 0-2 Yes 
Myalgias Limit or prevent walking? .28 .56 0-3 0-2 No* 
Myalgias Limit or prevent work 
activity? 
.31 .66 0-3 0-3 No 
Myalgias Limit or prevent social 
activity? 
.18 .48 0-3 0-2 No 
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Cramps Severity, usually when you 
have them? 
3.91 3.51 0-10 0-10 Yes 
Cramps Impact your emotional well-
being? 
.37 .73 0-3 0-3 Yes 
Cramps When during the day? 1.91 1.70 0-4 0-4 Yes 
Cramps How much of the time (daily 
vs. weekly vs. monthly)? 
2.67 2.74 0-9 0-9 Yes 
Cramps Limit or prevent physical 
activities? 
.38 .72 0-3 0-3 Yes 
Cramps Limit or prevent sitting or 
standing? 
.28 .60 0-3 0-3 Yes 
Cramps Limit or prevent walking? .25 .53 0-3 0-2 No* 
Cramps Limit or prevent work 
activity? 
.24 .54 0-3 0-3 No* 
Cramps Limit or prevent social 
activity? 
.13 .42 0-3 0-3 No* 
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Weakness How much of the time (daily 
vs. weekly vs. monthly)? 
2.09 3.17 0-9 0-9 Yes 
Weakness Severity usually or most of 
the time? 
1.80 2.50 0-9 0-10 Yes 
Weakness Make you need to take 
naps or sleep longer? 
.28 .73 0-3 0-3 Yes 
Weakness Impact your emotional well-
being? 
.35 .62 0-3 0-3 Yes 




0-3 0-3 Yes 
Weakness Limit or prevent sitting or 
standing?  
.20 .49 0-3 0-3 Yes 
Weakness Limit or prevent walking? .22 .50 0-3 0-3 No 
Weakness Limit or prevent work 
activity? 
.30 .65 0-3 0-3 No* 
Weakness Limit or prevent social 
activity? 
.18 .42 0-3 0-2 No* 
* Item loaded strongly on one subscale but was not included in the final measure because it did 
not increase the explained variance or contribute to improved reliability of the subscale. 
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Table 3. Principal components analysis pattern matrix factor loadings  
of the final promax rotation for the Muscle and Joint Measure 
Item content by subscale Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Arthralgias      
How much of the time (during the 
day/week/month)? 
0.96 -0.03 -0.05 0.13 -0.22 
Severity usually or most of the time? 1.01 -0.06 -0.01 0.01 -0.07 
Wake you when are sleeping? 0.75 0.12 0.06 0.02 -0.05 
Impact your emotional well-being? 0.71 -0.04 -0.06 -0.09 0.36 
Limit or prevent physical activities?  0.88 0.11 -0.07 0.01 -0.01 
Limit or prevent sitting or standing? 0.88 -0.12 0.08 -0.02 0.10 
Myalgias      
How much of the time (during the 
day/week/month)? 
-0.14 0.00 1.03 0.04 -0.17 
Severe usually or most of the time? 0.02 -0.04 0.94 0.03 -0.08 
Wake you or when you are sleeping? -0.05 0.03 0.77 0.14 0.07 
Impact your emotional well-being? -0.06 -0.05 0.69 -0.14 0.44 
Limit or prevent physical activities?  0.22 0.18 0.72 -0.09 -0.05 
Limit or prevent sitting or standing?  0.29 -0.03 0.59 -0.09 0.15 
Cramps      
When (during the day)? -0.01 -0.07 0.01 0.90 0.03 
How much of the time (during the 
day/week/month)? 
0.10 0.04 0.01 0.89 -0.13 
Severity usually when you have them? 0.02 -0.01 -0.06 0.82 0.18 
Wake you when you are sleeping?  -0.01 0.08 0.20 0.54 0.21 
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Table 3. Principal components analysis pattern matrix factor loadings  
of the final promax rotation for the Muscle and Joint Measure cont’d 
Item content by subscale Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Impact your emotional well-being? -0.09 -0.04 0.06 0.14 0.86 
Limit or prevent physical activities?  0.08 0.16 -0.06 0.07 0.72 
Limit or prevent sitting or standing?  -0.05 -0.11 -0.04 -0.02 0.98 
Weakness      
How much of the time (during the 
day/week/month)? 
-0.13 1.02 0.03 0.05 -.28 
Severity usually or most of the time? 0.00 0.94 -0.02 -0.05 0.01 
Make you need to take naps or sleep 
longer? 
-0.02 0.69 0.12 0.06 0.00 
Impact your emotional well-being? -0.02 0.77 -0.16 -0.03 0.37 
Limit or prevent physical activities?  0.12 0.82 0.09 -0.06 -0.09 
Limit or prevent sitting or standing?  0.09 0.72 -0.06 0.00 0.19 
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Arthralgias 6 0.78 
(1.03) 
55 74.9% 0.90 
Myalgias  6 0.89 
(1.06) 
52 73.5% 0.89 
Cramps 7 1.07 
(0.95) 
38 77.2% 0.86 
Weakness 6 0.67 
(0.93) 
61 71.9% 0.89 
Total score 25 0.85 
(0.76) 
15 76.8% 0.93 
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* All p <.001 





Arthralgias Myalgias Cramps 
Arthralgias  .82 --   
Myalgias .80 .53 --  
Cramps  .72 .47 .47 -- 
Weakness .72 .50 .44 .30 
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Table 6. Validation of the Muscle and Joint Measure (MJM) with other patient reported outcomes. 
* All P<.001 unless otherwise noted. 





Arthralgias Myalgias Cramps Weakness 
SF-36: Physical Function  
T score 
-.58 -.47 -.41 -.38 -.52 
SF-36: Bodily Pain  
T score 
-.80 -.67 -.68 -.59 -.53 
SCL-90-R Depression .65 .47 .58 .45 .52 
SF-36: Vitality T score -.57 -.40 -.53 -.38 -.49 
Fatigue Symptom 
Inventory Total 
.72 .47 .62 .51 .63 
Predicted Divergent 
Validity Measures 
     
SCL-90-R Anxiety .50 .39 .43 .37 .35 
SF-36: Mental Health  
T score 
-.49 -.29 (.002) -.52 -.29 (.004) -.41 
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18 Ineligible after screening
28 Active or passive refusal
144 Responded to PRO assessment  
(84% of potentially eligible cohort) 
14 Partial assessment completed
130 Completed PRO assessment, included in analyses 
(76% of potentially eligible cohort) 
190 Met initial eligibility criteria and contacted; 5 to 20-
year survivor, age 18-49 at first contact, hematologic 
malignancy, regional address
 
